Background:The incidence of device-related osteoarticular infections (DROI) is expected to rise, according to the increasing number of devices implanted. The appearance of DROI increases economic costs of arthroplasty and greatly affects the patientś life quality. The aim of this study is to describe the etiology and patterns of antibiotic sensitivity of the microbiological isolates, the surgical and medical treatment, and the clinical evolution of first episode of DROI episodes.Methods & Materials: Retrospective descriptive study of patients with DROI between July 2015 and December 2016. The microbiological diagnosis was performed by mass spectrometry, automated antibiogram and agar diffusion confirmation. Quantitative variables are reported as median and interquartile range(ICR), and categorical variables are reported as n and percent. For statistical analysis EpiInfo7.2 ® was used.Results: During the analyzed period, 32 patients were treated for DROI in our center, 18(56%) were women. The median age was 67 years(ICR 44-74). Thirteen(41%) patients had at least 1 risk factor. Twelve(37.4%) had early infections. Twenty-five(78%) had prosthetic joint infections and 7(22%) had device-related spine infections. The most frequently affected joints were: hip: 17(68%), knee: 6(24%), others: 2(8%). Surgical interventions were: toilette with material retention: 14(45%), toilette with material partial removal: 2(6%) and toilette with material removal: 15(49%). Most frequent microbiological isolates (n = 31): Staphylococcus aureus(S.aureus): 14(45%), coagulase-negative staphylococcus(CoNS): 9(29%), Enterobacteriaceae: 4(13%). Fifty percent of S.aureus were methicillin-resistant. Eight of 9 CoNS were found in late infections. Antibiotic resistance is reported in table 1. Mean intravenous treatment days was 14. Median oral treatment months was 4(ICR 3-6).
Background: Peginterferon alpha-2a is a known standard therapy for patients with acute HCV infection. Our experience with peginterferon in hemodialised patients with hepatitis C started with a million question and uncertainties. This because of the: -acute phase of infection,which we encountered due to repetitive serological tests the patients underwent because of hemodialysis protocols.-fragile,immunodepressed patients which had a lifetime with serious underlying diseases,primary related to nephropathies or not.However efficacy and safety of this treatment is still unclear in regional settings. This study tends to evidence the efficacy and safety of peg-interferon therapy in Albanian hemodialysed patients.Methods & Materials: In a one-year period (from November 2013-November 2014), we enrolled consecutive patients with detectable anti-HCV antibody and HCV-RNA in the serum, who had elevated serum alanine aminotransferase (ALT). Written informed consent was taken from them. Patients with decompensated cirrhosis were excluded and in women of fertility age,pregnancy tests were done 24 hours prior to the first dose of peginterferon alpha-2a. Underlying diseases in our hemodialysed patients included Chronic renal failure -55 cases, Acute pyelonephritis -1 case, Renal policystosis -6 cases,Congenital renal atrophy -1 case, nephrolythiasis -2 cases, renal transplant-2 cases, nephroectomy-3 cases, Arterial hypertension-2 cases, spondyloarthrosis -1 case.Results: Early virologic response and sustained virologic response rates were 84.8% (47/55) 78.2% (42/55) respectively. The most common adverse effects in descending order were flue-like symptoms (83%), hair loss 36.3%, anorexia 54.5%, weight loss 25.4%, mood changes 40%, sleep disorders 29%, hematomas 41%, epistaxis 21.8% Laboratory data evidenced anemia 96.3%, leucopenia 78.1%, thrombocytopenia 83.6%.Conclusion: Our 55 patients manifested several adverse effects, during therapy with peginterferon alpha-2a. Despite their particular immune status, these adverse affects appeared minimal compared to the efficacy of treatment in our patients
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.